Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy BNTC Stock  Free BNTC Stock Alerts

Benitec Biopharma (BNTC) Financials

Benitec Biopharma logo
$13.93 -0.05 (-0.36%)
As of 05/20/2025 04:00 PM Eastern
Compare
Annual Income Statements for Benitec Biopharma

Annual Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 6/30/2024 6/30/2023 6/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -22 -20 -18
Consolidated Net Income / (Loss)		 -22 -20 -18
Net Income / (Loss) Continuing Operations		 -22 -20 -18
Total Pre-Tax Income 		-22 -20 -18
Total Operating Income		 -22 -19 -18
Total Gross Profit		 0.00 0.08 0.07
Total Revenue		 0.00 0.08 0.07
Operating Revenue		 0.00 0.08 0.07
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 22 19 18
Selling, General & Admin Expense		 6.99 6.38 6.65
Research & Development Expense		 16 13 11
Other Operating Expenses / (Income)		 -0.11 0.00 0.01
Total Other Income / (Expense), net		 0.74 -0.48 -0.35
Interest & Investment Income		 0.90 -0.03 -0.03
Other Income / (Expense), net		 -0.17 -0.45 -0.32
Preferred Stock Dividends Declared		 0.62 - -
Basic Earnings per Share		 ($5.51) ($14.12) ($37.88)
Weighted Average Basic Shares Outstanding		 4.06M 1.39M 480.69K
Diluted Earnings per Share		 ($5.51) ($14.12) ($37.88)
Weighted Average Diluted Shares Outstanding		 4.06M 1.39M 480.69K
Weighted Average Basic & Diluted Shares Outstanding		 10.56M 2.55M 8.17M

Quarterly Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 12/31/2024 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -5.06 -5.34 -4.28 -7.36 -6.57 -4.66 -4.40 -5.41 -5.09 -5.07 -3.28
Consolidated Net Income / (Loss)		 -5.06 -4.72 -4.28 -7.36 -5.95 -4.66 -4.40 -5.41 -5.09 -5.07 -3.28
Net Income / (Loss) Continuing Operations		 -5.06 -4.72 -4.28 -7.36 -5.95 -4.66 -4.40 -5.41 -5.09 -5.07 -3.28
Total Pre-Tax Income 		-5.06 -4.72 -4.28 -7.36 -5.95 -4.66 -4.40 -5.41 -5.09 -5.07 -3.28
Total Operating Income		 -5.79 -5.55 -4.14 -8.61 -5.87 -4.55 -4.34 -5.61 -4.58 -4.74 -3.46
Total Gross Profit		 0.00 - 0.00 0.00 0.00 0.01 0.05 0.01 0.00 - 0.05
Total Revenue		 0.00 - 0.00 0.00 0.00 0.01 0.05 0.01 0.00 - 0.05
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.05 0.01 - - 0.05
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.79 5.55 4.14 8.61 5.87 4.56 4.40 5.62 4.58 4.74 3.51
Selling, General & Admin Expense		 2.21 2.04 1.58 3.54 1.55 1.37 1.23 1.86 1.92 1.55 1.34
Research & Development Expense		 3.59 3.51 2.57 5.07 4.43 3.19 3.17 3.76 2.66 3.18 2.17
Other Operating Expenses / (Income)		 0.00 - -0.00 0.00 -0.11 - 0.00 0.00 0.00 - -
Total Other Income / (Expense), net		 0.73 0.83 -0.14 1.25 -0.08 -0.11 -0.06 0.20 -0.51 -0.33 0.19
Interest & Investment Income		 0.60 0.92 -0.00 0.82 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01
Other Income / (Expense), net		 0.13 -0.09 -0.13 -0.33 -0.07 -0.10 -0.05 0.21 -0.50 -0.32 0.20
Preferred Stock Dividends Declared		 0.00 - - 0.00 0.62 - - - - - -
Basic Earnings per Share		 ($0.48) ($1.31) ($1.64) ($0.33) ($3.05) ($3.36) ($2.67) ($3.34) ($7.98) ($10.54) ($0.40)
Weighted Average Basic Shares Outstanding		 10.64M 4.06M 2.62M 22.08M 2.16M 1.39M 1.65M 1.62M 638.57K 480.69K 8.17M
Diluted Earnings per Share		 ($0.48) ($1.31) ($1.64) ($0.33) ($3.05) ($3.36) ($2.67) ($3.34) ($7.98) ($10.54) ($0.40)
Weighted Average Diluted Shares Outstanding		 10.64M 4.06M 2.62M 22.08M 2.16M 1.39M 1.65M 1.62M 638.57K 480.69K 8.17M
Weighted Average Basic & Diluted Shares Outstanding		 23.22M 10.56M 9.37M 23.45M 2.57M 2.55M 27.98M 27.98M 27.98M 8.17M 8.17M

Annual Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 6/30/2024 6/30/2023 6/30/2022
Net Change in Cash & Equivalents		 48 -1.59 -16
Net Cash From Operating Activities		 -19 -18 -16
Net Cash From Continuing Operating Activities		 -19 -18 -16
Net Income / (Loss) Continuing Operations		 -22 -20 -18
Consolidated Net Income / (Loss)		 -22 -20 -18
Depreciation Expense		 0.09 0.14 0.17
Amortization Expense		 0.26 0.25 0.23
Non-Cash Adjustments To Reconcile Net Income		 0.83 0.46 0.88
Changes in Operating Assets and Liabilities, net		 1.17 0.71 1.04
Net Cash From Investing Activities		 -0.18 -0.00 -0.01
Net Cash From Continuing Investing Activities		 -0.18 -0.00 -0.01
Purchase of Property, Plant & Equipment		 -0.18 -0.00 -0.01
Net Cash From Financing Activities		 68 16 0.00
Net Cash From Continuing Financing Activities		 68 16 0.00
Repurchase of Common Equity		 -5.89 -1.87 0.00
Issuance of Common Equity		 74 18 0.00
Effect of Exchange Rate Changes		 -0.01 0.41 0.20

Quarterly Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Net Change in Cash & Equivalents		 17 37 -6.23 -5.49 23 -4.08 -3.99 -6.00 12 -4.57 -3.70
Net Cash From Operating Activities		 -4.59 -3.29 -6.17 -5.37 -4.58 -4.10 -4.03 -5.84 -4.05 -4.86 -3.42
Net Cash From Continuing Operating Activities		 -4.59 -3.29 -6.17 -5.37 -4.58 -4.10 -4.03 -5.84 -4.05 -4.86 -3.42
Net Income / (Loss) Continuing Operations		 -5.06 -4.72 -4.28 -6.80 -5.95 -4.66 -4.40 -5.41 -5.09 -5.07 -3.27
Consolidated Net Income / (Loss)		 -5.06 -4.72 -4.28 -6.80 -5.95 -4.66 -4.40 -5.41 -5.09 -5.07 -3.27
Depreciation Expense		 0.03 0.03 0.03 0.02 0.02 0.02 0.03 0.04 0.04 0.01 0.05
Amortization Expense		 0.07 0.07 0.07 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Non-Cash Adjustments To Reconcile Net Income		 0.44 0.45 0.19 0.09 0.09 0.31 0.01 -0.11 0.24 0.31 0.06
Changes in Operating Assets and Liabilities, net		 -0.05 0.88 -2.17 1.26 1.20 0.17 0.26 -0.43 0.71 -0.16 -0.32
Net Cash From Investing Activities		 0.00 - -0.18 - 0.00 -0.00 - - 0.00 -0.01 -
Net Cash From Continuing Investing Activities		 0.00 - -0.18 - 0.00 -0.00 - - 0.00 -0.01 -
Net Cash From Financing Activities		 22 40 - 0.04 28 - - - 16 - -
Net Cash From Continuing Financing Activities		 22 40 - 0.04 28 - - - 16 - -
Repurchase of Common Equity		 0.00 -2.93 - - -2.96 - - - -1.87 - -
Other Financing Activities, net		 22 - - 0.04 31 - - - - - -
Effect of Exchange Rate Changes		 -0.09 -0.01 0.12 -0.16 0.05 0.02 0.04 -0.15 0.50 0.30 -0.28

Annual Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 6/30/2024 6/30/2023 6/30/2022
Total Assets		 52 4.46 5.97
Total Current Assets		 52 3.73 4.82
Cash & Equivalents		 51 2.48 4.06
Restricted Cash		 0.06 0.01 0.01
Accounts Receivable		 0.23 0.06 0.00
Prepaid Expenses		 0.52 1.18 0.74
Plant, Property, & Equipment, net		 0.18 0.09 0.22
Total Noncurrent Assets		 0.36 0.65 0.93
Other Noncurrent Operating Assets		 0.36 0.65 0.93
Total Liabilities & Shareholders' Equity		 52 4.46 5.97
Total Liabilities		 4.96 4.26 3.09
Total Current Liabilities		 4.92 3.98 2.53
Accounts Payable		 4.17 3.23 1.88
Current Employee Benefit Liabilities		 0.48 0.47 0.40
Other Current Liabilities		 0.28 0.28 0.25
Total Noncurrent Liabilities		 0.04 0.28 0.56
Noncurrent Employee Benefit Liabilities		 0.04 0.00 -
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 47 0.20 2.88
Total Preferred & Common Equity		 47 0.20 2.88
Preferred Stock		 0.00 - -
Total Common Equity		 47 0.20 2.88
Common Stock		 238 169 152
Retained Earnings		 -190 -168 -148
Accumulated Other Comprehensive Income / (Loss)		 -0.89 -0.83 -1.25

Quarterly Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 3/31/2024 12/31/2024 9/30/2023 3/31/2023 12/31/2022 9/30/2022 3/31/2022
Total Assets		 69 15 79 27 8.22 12 18 10
Total Current Assets		 68 14 79 26 7.40 11 17 8.84
Cash & Equivalents		 68 14 78 26 6.55 11 17 8.63
Restricted Cash		 0.06 0.01 0.06 0.01 0.01 0.01 0.01 -
Accounts Receivable		 0.00 0.05 0.00 0.05 0.06 0.07 0.00 0.01
Prepaid Expenses		 0.43 0.16 0.37 0.48 0.77 0.36 0.53 0.21
Plant, Property, & Equipment, net		 0.15 0.20 0.15 0.07 0.11 0.14 0.18 0.21
Total Noncurrent Assets		 0.29 0.43 0.20 0.57 0.72 0.79 0.86 1.01
Other Noncurrent Operating Assets		 0.29 0.43 0.20 0.57 0.72 0.79 0.86 1.01
Total Liabilities & Shareholders' Equity		 69 15 79 27 8.22 12 18 10
Total Liabilities		 4.59 3.50 3.13 4.75 3.51 2.91 3.50 2.54
Total Current Liabilities		 4.55 3.44 3.09 4.53 3.15 2.49 3.01 1.91
Accounts Payable		 3.85 2.63 2.42 3.79 2.46 1.83 2.37 1.32
Current Employee Benefit Liabilities		 0.50 0.52 0.54 0.46 0.43 0.40 0.39 0.36
Other Current Liabilities		 0.21 0.29 0.14 0.28 0.27 0.26 0.26 0.23
Total Noncurrent Liabilities		 0.04 0.06 0.04 0.21 0.35 0.42 0.49 0.64
Noncurrent Employee Benefit Liabilities		 0.04 - 0.04 - - - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 64 12 76 22 4.71 8.99 15 7.52
Total Preferred & Common Equity		 64 12 76 22 4.71 8.99 15 7.52
Total Common Equity		 64 12 76 22 4.71 8.99 15 7.52
Common Stock		 260 197 279 197 169 169 169 152
Retained Earnings		 -195 -185 -203 -174 -163 -159 -153 -143
Accumulated Other Comprehensive Income / (Loss)		 -0.99 -0.84 -0.69 -0.78 -0.85 -0.90 -0.74 -1.51

Annual Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric 2024 2023 2022
Period end date 6/30/2024 6/30/2023 6/30/2022
Growth Metrics		 - - -
Revenue Growth		 -100.00% 2.74% 23.73%
EBITDA Growth		 -16.52% -7.67% -32.20%
EBIT Growth		 -16.01% -7.44% -30.99%
NOPAT Growth		 -17.87% -6.87% -31.32%
Net Income Growth		 -11.19% -7.44% -31.16%
EPS Growth		 60.98% -7.44% -31.16%
Operating Cash Flow Growth		 -7.72% -13.29% -23.90%
Free Cash Flow Firm Growth		 -17.02% -10.70% -19.04%
Invested Capital Growth		 -60.88% -91.62% -628.32%
Revenue Q/Q Growth		 -100.00% 10.29% 0.00%
EBITDA Q/Q Growth		 -4.59% 2.17% -7.26%
EBIT Q/Q Growth		 -4.56% 2.03% -6.84%
NOPAT Q/Q Growth		 -4.64% 0.97% -5.20%
Net Income Q/Q Growth		 -0.27% 2.03% -6.21%
EPS Q/Q Growth		 33.53% 2.03% -6.21%
Operating Cash Flow Q/Q Growth		 3.97% 4.05% 1.86%
Free Cash Flow Firm Q/Q Growth		 -0.77% 3.79% 6.34%
Invested Capital Q/Q Growth		 -38.59% -23.54% -7.57%
Profitability Metrics		 - - -
Gross Margin		 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% -25,530.67% -24,361.64%
Operating Margin		 0.00% -25,441.33% -24,457.53%
EBIT Margin		 0.00% -26,038.67% -24,898.63%
Profit (Net Income) Margin		 0.00% -26,082.67% -24,942.47%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 96.01% 100.17% 100.18%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -91.68% -1,268.61% -159.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -374.23% -132.90%
Return on Assets (ROA)		 0.00% -374.86% -133.14%
Return on Common Equity (ROCE)		 -91.68% -1,268.61% -159.08%
Return on Equity Simple (ROE_SIMPLE)		 -46.04% 0.00% -631.78%
Net Operating Profit after Tax (NOPAT)		 -16 -13 -12
NOPAT Margin		 0.00% -17,808.93% -17,120.27%
Net Nonoperating Expense Percent (NNEP)		 -22.49% -189.01% -47.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 8,509.33% 9,104.11%
R&D to Revenue		 0.00% 17,032.00% 15,441.10%
Operating Expenses to Revenue		 0.00% 25,541.33% 24,557.53%
Earnings before Interest and Taxes (EBIT)		 -23 -20 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -19 -18
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.39 33.04 3.29
Price to Tangible Book Value (P/TBV)		 1.39 33.04 3.29
Price to Revenue (P/Rev)		 0.00 88.98 129.85
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 55.78 74.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.13 -2.13 -1.04
Leverage Ratio		 1.19 3.38 1.19
Compound Leverage Factor		 1.15 3.39 1.20
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 2.46 -66.20 -42.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 10.49 0.94 1.90
Quick Ratio		 10.38 0.64 1.61
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -14 -12 -11
Operating Cash Flow to CapEx		 -10,839.66% -1,801,200.00% -122,300.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.01 0.01
Accounts Receivable Turnover		 0.00 2.59 5.21
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.49 0.24
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 141.13 70.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 141.13 70.00
Capital & Investment Metrics		 - - -
Invested Capital		 -3.68 -2.29 -1.19
Invested Capital Turnover		 0.00 -0.04 -0.15
Increase / (Decrease) in Invested Capital		 -1.39 -1.09 -1.42
Enterprise Value (EV)		 15 4.18 5.40
Market Capitalization		 65 6.67 9.48
Book Value per Share		 $5.04 $0.01 $0.35
Tangible Book Value per Share		 $5.04 $0.01 $0.35
Total Capital		 47 0.20 2.88
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -51 -2.49 -4.08
Capital Expenditures (CapEx)		 0.18 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.18 -2.74 -1.79
Debt-free Net Working Capital (DFNWC)		 47 -0.25 2.29
Net Working Capital (NWC)		 47 -0.25 2.29
Net Nonoperating Expense (NNE)		 6.01 6.21 5.71
Net Nonoperating Obligations (NNO)		 -51 -2.49 -4.08
Total Depreciation and Amortization (D&A)		 0.34 0.38 0.39
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -3,652.00% -2,449.32%
Debt-free Net Working Capital to Revenue		 0.00% -332.00% 3,134.25%
Net Working Capital to Revenue		 0.00% -332.00% 3,134.25%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($5.51) ($14.12) ($37.91)
Adjusted Weighted Average Basic Shares Outstanding		 4.06M 1.39M 480.69K
Adjusted Diluted Earnings per Share		 ($5.51) ($14.12) ($37.91)
Adjusted Weighted Average Diluted Shares Outstanding		 4.06M 1.39M 480.69K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.56M 2.55M 480.69K
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -13 -12
Normalized NOPAT Margin		 0.00% -17,808.93% -17,120.27%
Pre Tax Income Margin		 0.00% -26,082.67% -24,942.47%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -27.09% -9.55% 0.00%

Quarterly Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 12/31/2024 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% -100.00% 0.00% 0.00% 12.50% -44.00% 0.00% 0.00% 2,300.00%
EBITDA Growth		 5.01% -21.45% 2.61% -67.25% -17.74% 8.51% -36.37% -12.84% -0.81% -31.73% 19.37%
EBIT Growth		 4.79% -21.21% 2.62% -65.57% -16.99% 7.99% -34.46% -12.31% -0.79% -29.90% 18.84%
NOPAT Growth		 1.41% -21.93% 4.61% -53.48% -28.25% 3.95% -25.46% -16.03% 5.02% 13.96% 8.78%
Net Income Growth		 15.03% -1.27% 2.68% -35.96% -16.91% 8.01% -34.26% -12.24% -0.95% -26.58% 16.22%
EPS Growth		 84.26% 61.01% 38.58% 90.12% 61.78% 8.01% -34.26% -12.24% -0.95% -26.58% 51.22%
Operating Cash Flow Growth		 -0.20% 19.58% -53.09% 8.18% -13.15% 15.65% -17.74% -74.73% 5.45% 5.86% -72.05%
Free Cash Flow Firm Growth		 -57.37% -19.11% 8.80% -34.09% -62.52% -10.29% 3.09% -202.62% 46.29% 47.96% -48.39%
Invested Capital Growth		 -4.37% -60.88% -43.41% -54.40% -84.54% -91.62% -66.85% -4.29% -667.46% -628.32% -4.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00% -87.04% 285.71% 0.00% 0.00% 0.00% 92.00%
EBITDA Q/Q Growth		 -0.41% -32.59% 37.65% -51.11% -28.39% -6.33% 18.92% -6.38% 0.24% -58.49% 32.91%
EBIT Q/Q Growth		 -0.41% -31.93% 37.06% -50.37% -27.83% -5.99% 18.73% -6.25% -0.53% -54.89% 32.12%
NOPAT Q/Q Growth		 -4.38% -33.98% 40.22% -46.58% -29.10% -4.81% 22.62% -22.49% 3.31% -36.91% 28.44%
Net Income Q/Q Growth		 -7.18% -10.31% 37.06% -23.56% -27.74% -6.00% 18.74% -6.24% -0.51% -54.72% 32.07%
EPS Q/Q Growth		 63.36% 20.12% 37.88% 89.18% 9.23% -6.00% 18.74% -6.24% -0.51% -54.72% 32.20%
Operating Cash Flow Q/Q Growth		 -39.27% 46.61% -14.97% -17.22% -11.77% -1.64% 31.05% -44.45% 16.68% -41.88% -2.33%
Free Cash Flow Firm Q/Q Growth		 -56.50% -18.90% -40.78% -109.14% -18.45% 8.96% 40.55% -153.48% 19.62% 20.00% -85.66%
Invested Capital Q/Q Growth		 -1.20% -38.59% 45.99% 32.64% -55.99% -23.54% -18.95% 19.49% -61.98% -7.57% 25.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -65,271.43% -7,957.41% -37,857.14% 0.00% 0.00% -6,564.58%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -65,000.00% -8,038.89% -40,071.43% 0.00% 0.00% -7,208.33%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -66,471.43% -8,129.63% -38,585.71% 0.00% 0.00% -6,802.08%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -66,585.71% -8,142.59% -38,650.00% 0.00% 0.00% -6,822.92%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 89.33% 83.69% 100.09% 82.26% 100.10% 100.17% 100.16% 100.17% 100.18% 100.20% 100.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -48.23% -91.68% -267.59% -52.67% -110.63% -1,268.61% -326.46% -190.08% -121.35% -159.08% -185.84%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -955.32% -60.47% -184.60% 0.00% 0.00% -42.27%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -956.97% -60.57% -184.91% 0.00% 0.00% -42.40%
Return on Common Equity (ROCE)		 -48.23% -91.68% -267.59% -52.67% -110.63% -1,268.61% -326.46% -190.08% -121.35% -159.08% -185.84%
Return on Equity Simple (ROE_SIMPLE)		 -32.50% 0.00% -188.63% -29.46% -91.55% 0.00% -423.68% -209.54% -124.93% 0.00% -227.98%
Net Operating Profit after Tax (NOPAT)		 -4.05 -3.88 -2.90 -6.03 -4.11 -3.19 -3.04 -3.93 -3.21 -3.32 -2.42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -45,500.00% -5,627.22% -28,050.00% 0.00% 0.00% -5,045.83%
Net Nonoperating Expense Percent (NNEP)		 -2.14% -3.13% -13.32% -2.99% -8.68% -44.96% -17.88% -12.97% -11.69% -14.68% -8.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 19,585.71% 2,274.07% 13,307.14% 0.00% 0.00% 2,785.42%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 45,514.29% 5,864.81% 26,864.29% 0.00% 0.00% 4,522.92%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 65,100.00% 8,138.89% 40,171.43% 0.00% 0.00% 7,308.33%
Earnings before Interest and Taxes (EBIT)		 -5.66 -5.64 -4.28 -8.94 -5.95 -4.65 -4.39 -5.40 -5.08 -5.06 -3.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.57 -5.55 -4.19 -8.86 -5.87 -4.57 -4.30 -5.30 -4.98 -4.99 -3.15
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.51 1.39 1.18 3.86 0.35 33.04 1.25 0.53 0.21 3.29 2.54
Price to Tangible Book Value (P/TBV)		 1.51 1.39 1.18 3.86 0.35 33.04 1.25 0.53 0.21 3.29 2.54
Price to Revenue (P/Rev)		 0.00 0.00 1,944.33 4,806.94 102.63 88.98 86.37 76.72 41.61 129.85 261.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 3,522.60 0.00 55.78 0.00 0.00 0.00 74.02 143.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.13 -1.28 -1.05 -1.15 -2.13 -1.24 -1.15 -1.07 -1.04 -1.12
Leverage Ratio		 1.11 1.19 1.43 1.07 1.22 3.38 1.49 1.31 1.19 1.19 1.27
Compound Leverage Factor		 0.99 1.00 1.43 0.88 1.22 3.39 1.50 1.31 1.20 1.20 1.28
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.53 3.53 -14.99 53.45 -7.78 -55.20 -27.93 -18.33 -11.33 -35.25 -15.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.01 10.49 4.18 25.48 5.83 0.94 2.35 4.41 5.67 1.90 4.63
Quick Ratio		 14.90 10.38 4.13 25.34 5.72 0.64 2.10 4.26 5.49 1.61 4.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.90 -2.49 -2.09 -5.18 -2.48 -2.09 -2.30 -3.86 -1.52 -1.90 -2.37
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -409,500.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.13 1.74 2.68 2.59 2.23 1.70 24.33 5.21 9.73
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.05 0.42 0.61 0.49 0.43 0.30 0.29 0.24 0.19
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 2,841.79 209.43 136.27 141.13 163.71 214.88 15.00 70.00 37.50
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50,567.71
Cash Conversion Cycle (CCC)		 0.00 0.00 2,841.79 209.43 136.27 141.13 163.71 214.88 15.00 70.00 -50,530.21
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.73 -3.68 -2.66 -2.40 -3.57 -2.29 -1.85 -1.56 -1.93 -1.19 -1.11
Invested Capital Turnover		 0.00 0.00 0.00 -0.03 -0.03 -0.04 -0.05 -0.04 -0.07 -0.15 -0.07
Increase / (Decrease) in Invested Capital		 -0.16 -1.39 -0.80 -0.85 -1.64 -1.09 -0.74 -0.06 -1.68 -1.42 -0.05
Enterprise Value (EV)		 29 15 -0.55 215 -18 4.18 -0.69 -5.79 -14 5.40 10
Market Capitalization		 97 65 14 293 7.70 6.67 5.87 4.76 3.04 9.48 19
Book Value per Share		 $6.08 $5.04 $4.44 $3.27 $8.76 $0.01 $0.17 $0.32 $1.79 $0.35 $0.92
Tangible Book Value per Share		 $6.08 $5.04 $4.44 $3.27 $8.76 $0.01 $0.17 $0.32 $1.79 $0.35 $0.92
Total Capital		 64 47 12 76 22 0.20 4.71 8.99 15 2.88 7.52
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -68 -51 -14 -78 -26 -2.49 -6.57 -11 -17 -4.08 -8.63
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.12 -4.18 -3.23 -2.72 -4.00 -2.74 -2.32 -2.07 -2.48 -1.79 -1.70
Debt-free Net Working Capital (DFNWC)		 64 47 11 76 22 -0.25 4.24 8.49 14 2.29 6.93
Net Working Capital (NWC)		 64 47 11 76 22 -0.25 4.24 8.49 14 2.29 6.93
Net Nonoperating Expense (NNE)		 1.01 0.84 1.38 1.33 1.84 1.48 1.36 1.48 1.89 1.75 0.85
Net Nonoperating Obligations (NNO)		 -68 -51 -14 -78 -26 -2.49 -6.57 -11 -17 -4.08 -8.63
Total Depreciation and Amortization (D&A)		 0.09 0.09 0.09 0.08 0.08 0.08 0.09 0.10 0.10 0.06 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -46,100.00% -4,460.66% -5,332.00% -3,652.00% -3,416.18% -3,330.65% -3,393.15% -2,449.32% -2,326.03%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 156,128.57% 123,973.77% 29,170.67% -332.00% 6,238.24% 13,687.10% 19,273.97% 3,134.25% 9,495.89%
Net Working Capital to Revenue		 0.00% 0.00% 156,128.57% 123,973.77% 29,170.67% -332.00% 6,238.24% 13,687.10% 19,273.97% 3,134.25% 9,495.89%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($1.31) ($1.64) ($0.33) ($2.76) ($57.12) ($2.72) ($3.40) ($7.99) ($179.18) ($6.80)
Adjusted Weighted Average Basic Shares Outstanding		 10.64M 4.06M 2.62M 22.08M 2.16M 81.52K 1.65M 1.62M 638.57K 28.28K 480.69K
Adjusted Diluted Earnings per Share		 ($0.48) ($1.31) ($1.64) ($0.33) ($2.76) ($57.12) ($2.72) ($3.40) ($7.99) ($179.18) ($6.80)
Adjusted Weighted Average Diluted Shares Outstanding		 10.64M 4.06M 2.62M 22.08M 2.16M 81.52K 1.65M 1.62M 638.57K 28.28K 480.69K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.31) $0.00 $0.00 $0.00 ($57.12) $0.00 $0.00 $0.00 ($179.18) ($6.80)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 23.22M 10.56M 9.37M 23.45M 2.57M 149.85K 1.65M 1.65M 1.65M 480.69K 480.69K
Normalized Net Operating Profit after Tax (NOPAT)		 -4.05 -3.88 -2.90 -6.03 -4.11 -3.19 -3.04 -3.93 -3.21 -3.32 -2.42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -45,500.00% -5,627.22% -28,050.00% 0.00% 0.00% -5,045.83%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -66,585.71% -8,142.59% -38,650.00% 0.00% 0.00% -6,822.92%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -14.04% -27.09% -13.66% -13.25% -14.51% -9.55% -9.36% -9.92% -10.24% 0.00% -9.25%

Frequently Asked Questions About Benitec Biopharma's Financials

When does Benitec Biopharma's financial year end?

According to the most recent income statement we have on file, Benitec Biopharma's fiscal year ends in June. Their fiscal year 2024 ended on June 30, 2024.

How has Benitec Biopharma's net income changed over the last 2 years?

Benitec Biopharma's net income appears to be on an upward trend, with a most recent value of -$21.75 million in 2024, rising from -$18.21 million in 2022. The previous period was -$19.56 million in 2023. See where experts think Benitec Biopharma is headed by visiting Benitec Biopharma's forecast page.

What is Benitec Biopharma's operating income?
Benitec Biopharma's total operating income in 2024 was -$22.49 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $22.49 million
How has Benitec Biopharma revenue changed over the last 2 years?

Over the last 2 years, Benitec Biopharma's total revenue changed from $73 thousand in 2022 to $0.00 in 2024, a change of -100.0%.

How much debt does Benitec Biopharma have?

Benitec Biopharma's total liabilities were at $4.96 million at the end of 2024, a 16.4% increase from 2023, and a 60.5% increase since 2022.

How much cash does Benitec Biopharma have?

In the past 2 years, Benitec Biopharma's cash and equivalents has ranged from $2.48 million in 2023 to $50.87 million in 2024, and is currently $50.87 million as of their latest financial filing in 2024.

How has Benitec Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Benitec Biopharma's book value per share changed from 0.35 in 2022 to 5.04 in 2024, a change of 1,330.1%.


Related Companies

This page (NASDAQ:BNTC) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored